Published in Cell, a groundbreaking study reports a universal antivenom strategy using a 3-agent cocktail—two broadly neutralizing human antibodies plus varespladib—that protected against venom from 19 deadly snake species across 10 genera in the Elapidae family.
🔬 Key Highlights:
• Broadly neutralizing antibodies were isolated from a hyperimmune human exposed to multiple venoms
• These antibodies mimic the snake toxin’s target (nAChR) and block its function
• The cocktail neutralizes major neurotoxins (LNXs, SNXs) and enzymatic toxins (PLA2s)
• Potential to become the first human-derived universal antivenom, offering:
- Broader protection across species
- Reduced risk of serum sickness
- Longer half-life and improved safety
- Easier stockpiling and distribution
🌍 A universal antivenom could save over 100,000 lives/year, especially in regions lacking species-specific antivenoms. It also opens the door for recombinant antibody-based solutions for Viperidae and other toxin families.
📉 Limitations: Current findings are based on mouse models and standard venom doses; real-world efficacy in humans and high-dose bites still requires further validation.
This is a promising leap toward solving a long-standing neglected tropical disease and improving global health equity.
Source: https://www.cell.com/cell/fulltext/S0092-8674%2825%2900402-7
#Antivenom #Snakebite #CellPress #Immunotherapy #Varespladib #Antibodies #GlobalHealth #NeglectedDiseases #Elapidae #InnovationInBiotech
